澳大利亚成人流感疫苗接种预防心脏骤停的成本效益分析
该研究将澳大利亚健康与福利研究所的心脏骤停住院数据与已发表文献中的生存、疫苗接种和成本参数结合,建立模型估算为所有50-64岁澳大利亚成人普遍资助流感疫苗接种以预防心脏骤停死亡和住院的成本效益。敏感性分析调整统计生命年值并减少剩余生命年后,最低效益成本比为29.97,成本节约仍显著。结论认为从政府角度,将疫苗接种扩展至50-64岁成人以降低心脏骤停可能是一项成本效益良好的政策,但需要更准确的参数来提高这些估计的可靠性。
要点
- 模型估计为50-64岁成人普遍资助流感疫苗可预防278例心脏骤停住院和1269例心脏骤停死亡。
- 敏感性分析中最低效益成本比为29.97,成本节约仍显著。
核心结论
- 从政府角度,通过扩展疫苗接种(包括50-64岁成人)来减少心脏骤停可能是一项成本效益良好的政策。
- 心脏骤停死亡因高死亡率造成显著经济损失,远大于通过避免住院所节省的成本。
- 需要更准确的参数来提高这些估计的可靠性,但该模型可作为进一步研究心脏骤停经济影响的基础。
研究设计与样本
- 研究将澳大利亚健康与福利研究所(AIHW)的心脏骤停住院数据与已发表文献中的生存、疫苗接种和成本参数结合,建立模型估算为所有50-64岁澳大利亚成人普遍资助流感疫苗接种以预防心脏骤停死亡和住院的成本效益。
- 成本从政府角度考虑,包括疫苗和全科医生咨询费用,避免的死亡通过年龄调整的统计生命价值估算。
主要发现
- 目标政策估计可预防278例心脏骤停住院和1269例心脏骤停死亡。
- 大部分节省与避免的死亡相关。
- 敏感性分析通过改变统计生命年值并减少剩余生命年,成本节约仍显著,推导出的最低BCR为29.97。
局限性
- 需要更准确的参数来提高这些估计的可靠性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of the study was to estimate the economic cost benefit of funding influenza vaccination to all Australian adults 50-64 years and predict its effect on sudden cardiac arrest (SCA) deaths and hospitalisation. METHODS: We combined SCA hospitalisation data from the Australian Institute of Health and Welfare (AIHW) with survival, vaccination, and cost parameters from published literature to create a model estimating the cost benefit of universally funded influenza vaccinations to prevent SCA deaths and hospitalisation. Costs were considered from a government perspective and included cost of vaccines and GP consultations, whilst averted deaths were estimated through the age-adjusted value of a statistical life. RESULTS: The target policy was estimated to prevent 278 SCA hospitalisations and 1269 SCA deaths. This would result in cost-savings of almost $4 billion annually, with an incremental benefit-cost ratio (BCR) of 59.94. The majority of savings were associate with averted deaths. When a sensitivity analysis was performed by altering statistical life year values and reducing life years left, the cost-saving remained significant with a minimum BCR of 29.97 derived. CONCLUSIONS: Reducing SCA through extended vaccination including adults 50-64 years is likely to be a cost beneficial policy from a governmental perspective. SCA deaths account for a significant economic loss due to the high mortality rate, which was far greater than the costs saved through averted hospitalisations. More accurate parameters are needed to improve the reliability of these estimate; however, this model can be used as a basis for further research into the economic impact of SCA.
引用
- Wei J, Tan TC, Moa AM, et al. Cost-benefit of influenza vaccination in preventing sudden cardiac arrest amongst Australian adults. Vaccine. 2024. PMID: 38341292. doi:10.1016/j.vaccine.2024.02.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。